Executive summary

A study by the NCC, Korea group analyzed 81 patients with locally advanced pancreatic cancer (LAPC), treated with PBT simultaneous integrated boost (SIB) technique. The prescribed doses to planning target volume (PTV)1 and PTV2 were 45 or 50 GyE and 30 GyE in 10 fractions, respectively.

With the median follow-up time 19.6 months, the study reported that the median overall survival (OS) times of all patients and of those in groups I (no chemotherapy), II (with maintenance chemotherapy), and III (upfront and maintenance chemotherapy) were 19.3 months, 15.3 months, 18.3 months, and 26.1 months, respectively (p = 0.043). Acute and late grade ≥ 3 toxicities related to PBT were not observed. PBT with the SIB technique showed promising OS for LAPC patients with a safe toxicity profile, and intensive combinations of PBT and chemotherapy could improve OS in these patients.

Key content topics
Top cancer treatments